We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+24.54%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$787M
AUM Growth
+$143M
Cap. Flow
+$36.2M
Cap. Flow %
4.61%
Top 10 Hldgs %
62.09%
Holding
40
New
7
Increased
12
Reduced
8
Closed
4

Top Buys

Rank Stock Value
1
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$46.3M
2
ZEAL
Zealand Pharma A/S American Depositary Shares
ZEAL
+$18.8M
3
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$18.6M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$13.9M
5
KURA icon
Kura Oncology
KURA
+$12.7M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$31.2M
2
OMED
OncoMed Pharmaceuticals, Inc.
OMED
+$17.8M
3
LOXO
Loxo Oncology, Inc
LOXO
+$17.5M
4
ACHN
Achillion Pharmaceuticals
ACHN
+$16M
5
CYTK icon
Cytokinetics
CYTK
+$10.2M

Sector Composition

Rank Sector Weight
1 Healthcare 85.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FWP
26
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$8.57M 1.09%
207,874
+9,609
+5% +$1.33M
ARQL
27
DELISTED
Arqule Inc
ARQL
$8.21M 1.04%
7,400,128
– –
ALPN
28
DELISTED
Alpine Immune Sciences Inc
ALPN
$7.84M 1%
675,759
+14,557
+2% +$136K
CRVS icon
29
Corvus Pharmaceuticals
CRVS
$1.11B
$7.32M 0.93%
459,396
+185,200
+68% +$2.56M
MTEM
30
DELISTED
Molecular Templates, Inc.
MTEM
$5.05M 0.64%
+48,275
New +$4.17M
VIRX
31
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$3.96M 0.5%
58,377
+7,786
+15% +$636K
CFRX
32
DELISTED
ContraFect Corporation
CFRX
$3.88M 0.49%
+4,375
New +$4.14M
KDNY
33
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$1.97M 0.25%
36,953
-23,047
-38% -$1.37M
OREX
34
DELISTED
Orexigen Therapeutics, Inc.
OREX
$1.56M 0.2%
734,976
– –
ANTH
35
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$1.45M 0.18%
1,006,507
– –
FLNA
36
Filana Therapeutics
FLNA
$46.4M
$1.32M 0.17%
325,508
– –
FATE icon
37
Fate Therapeutics
FATE
$293M
– –
-391,386
Closed -$1.27M
ACHN
38
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-3,490,077
Closed -$16M
RXDX
39
DELISTED
Ignyta, Inc.
RXDX
– –
-700,000
Closed -$7.25M
1
2

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q3 2017 Portfolio in Review

As of Q3 2017, BVF Inc held 40 positions worth $787M, up 22% from $644M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

BVF Inc deployed $36.2M of net new capital in Q3 2017, opening 7 new positions and adding to 12 existing holdings. Its largest new stake was Ironwood Pharmaceuticals: 3,367,080 shares worth $44.5M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 79% a quarter earlier.

On the sell side, the largest reduction was Blueprint Medicines, an estimated $31.2M trimmed.

  • BVF Inc's largest Q3 2017 buy was Ironwood Pharmaceuticals: 3,367,080 shares worth $44.5M.
  • BVF Inc added most to Concert Pharmaceuticals, Inc. in Q3 2017, an estimated $18.6M increase.
  • BVF Inc's biggest Q3 2017 reduction was Blueprint Medicines, cutting an estimated $31.2M.
  • BVF Inc fully exited OncoMed Pharmaceuticals, Inc. in Q3 2017, selling an estimated $17.8M.
  • BVF Inc's ten largest holdings make up 62% of its $787M portfolio in Q3 2017.
  • BVF Inc opened 7 new positions and closed 4 in Q3 2017.
  • BVF Inc's portfolio value rose 22% quarter-over-quarter to $787M.

Based on BVF Inc's 13F filing for Q3 2017, filed 14 Nov 2017.